Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 14/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23932182 | 0.91 | MKNK1 (0.36) | CRHR1MKNK1DYRK1AFYN | |
| SCHEMBL23931871 | 0.85 | MKNK1 (0.36) | CRHR1MKNK1DYRK1AFYN | |
| SCHEMBL23931891 | 0.82 | SMN1; SMN2 (0.40) | MKNK1DYRK1AFYN | |
| SCHEMBL23931923 | 0.76 | PIM1 (0.47) | MKNK1FYN | |
| SCHEMBL23932000 | 0.75 | HCAR3 (0.41) | MKNK1 | |
| SCHEMBL15254587 | 0.70 | MKNK1 (0.44) | MKNK1 | |
| SCHEMBL23932033 | 0.70 | FFAR2 (0.34) | — | |
| SCHEMBL23931998 | 0.69 | SMN1; SMN2 (0.52) | — | |
| SCHEMBL20119801 | 0.69 | NTRK1 (0.39) | MKNK1 | |
| SCHEMBL23931849 | 0.68 | PIM1 (0.48) | MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | THE UAB RESEARCH FOUNDATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2021216757-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159542-A1 | RNA-BINDING PROTEIN MULTIMERIZATION INHIBITORS AND METHODS OF USE THEREOF | HNRNPR, HNRNPAB, RBM3 | CRHR1 2009/4885MKNK1 1675/4885DYRK1A 3007/4885 |
| US-12435091-B2 | RNA-binding protein multimerization inhibitors and methods of use thereof | HNRNPR, HNRNPAB, RBM3 | CRHR1 2009/4885MKNK1 1675/4885DYRK1A 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.